Equities research analysts at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for Metsera in a report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” Pipeline ...

Metsera ,” said Whit Bernard, CEO. “We advanced MET-097i, our monthly, fully-biased GLP-1 RA injectable, from f ...

Cash, cash equivalents and marketable securities were $352.4 million as of December 31, 2024, compared to $75.2 million as of December 31, ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera's portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” MET-097i is a fully ...

“2024 was a year of exceptional execution and acceleration at Metsera,” said Whit Bernard, Chief Executive Officer of Metsera.“We advanced MET-097i, our monthly, fully-biased GLP-1 RA ...